Trends in neuroprotection.
Pop
E
E
D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D017209:Apoptosis; D001927:Brain Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002186:Cannabinoids / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D015259:Dopamine Agents / Q000627:therapeutic use; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005128:Eye Diseases / Q000188:drug therapy*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy; D006801:Humans; D007429:Intraocular Pressure; D008559:Memantine / Q000627:therapeutic use; D051379:Mice; D015337:Multicenter Studies as Topic; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000188:drug therapy; D011281:Pregnatrienes / Q000627:therapeutic use; D051381:Rats
D000978:Antiparkinson Agents; D002121:Calcium Channel Blockers; D002186:Cannabinoids; C428064:DP-b99; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D011281:Pregnatrienes; D017311:Amlodipine; D004533:Egtazic Acid; D008559:Memantine; C053355:tirilazad